Published in J Cell Sci on November 01, 2001
Isolation and functional characterization of murine prostate stem cells. Proc Natl Acad Sci U S A (2006) 4.54
Trop2 identifies a subpopulation of murine and human prostate basal cells with stem cell characteristics. Proc Natl Acad Sci U S A (2008) 3.26
In vivo regeneration of murine prostate from dissociated cell populations of postnatal epithelia and urogenital sinus mesenchyme. Proc Natl Acad Sci U S A (2003) 3.19
Sca-1 expression identifies stem cells in the proximal region of prostatic ducts with high capacity to reconstitute prostatic tissue. Proc Natl Acad Sci U S A (2005) 2.77
The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells. Cancer Res (2008) 2.29
ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients' outcome. Lab Invest (2009) 2.25
Low-calcium serum-free defined medium selects for growth of normal prostatic epithelial stem cells. Cancer Res (2006) 2.02
Human prostate sphere-forming cells represent a subset of basal epithelial cells capable of glandular regeneration in vivo. Prostate (2010) 1.78
Stem cells in prostate cancer initiation and progression. J Clin Invest (2007) 1.76
Stem cell and neurogenic gene-expression profiles link prostate basal cells to aggressive prostate cancer. Nat Commun (2016) 1.65
Monoallelic expression of TMPRSS2/ERG in prostate cancer stem cells. Nat Commun (2013) 1.57
Telomeres and telomerase in normal and cancer stem cells. FEBS Lett (2010) 1.46
Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues. Br J Cancer (2005) 1.45
Estrogen receptor-beta activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNFalpha mediated. Proc Natl Acad Sci U S A (2010) 1.32
Purification and direct transformation of epithelial progenitor cells from primary human prostate. Nat Protoc (2011) 1.30
Molecular and cellular characterization of ABCG2 in the prostate. BMC Urol (2007) 1.26
Prostate cancer stem cells. J Pathol (2009) 1.26
Critical and distinct roles of p16 and telomerase in regulating the proliferative life span of normal human prostate epithelial progenitor cells. J Biol Chem (2008) 1.23
Integrin αv expression is required for the acquisition of a metastatic stem/progenitor cell phenotype in human prostate cancer. Am J Pathol (2011) 1.16
Anchorage-independent culture maintains prostate stem cells. Dev Biol (2007) 1.15
Characterization of adult prostatic progenitor/stem cells exhibiting self-renewal and multilineage differentiation. Stem Cells (2007) 1.14
Frequent gene products and molecular pathways altered in prostate cancer- and metastasis-initiating cells and their progenies and novel promising multitargeted therapies. Mol Med (2011) 1.13
Primitive origins of prostate cancer: in vivo evidence for prostate-regenerating cells and prostate cancer-initiating cells. Mol Oncol (2010) 1.11
Partial enrichment of a population of human limbal epithelial cells with putative stem cell properties based on collagen type IV adhesiveness. Exp Eye Res (2005) 1.09
Contributions of epithelial-mesenchymal transition and cancer stem cells to the development of castration resistance of prostate cancer. Mol Cancer (2014) 1.07
New therapy targeting differential androgen receptor signaling in prostate cancer stem/progenitor vs. non-stem/progenitor cells. J Mol Cell Biol (2012) 1.07
Integrin alpha2beta 1 (α2β1) promotes prostate cancer skeletal metastasis. Clin Exp Metastasis (2012) 1.05
Glioblastoma multiforme: a perspective on recent findings in human cancer and mouse models. BMB Rep (2011) 1.04
The aldehyde dehydrogenase enzyme 7A1 is functionally involved in prostate cancer bone metastasis. Clin Exp Metastasis (2011) 1.03
Identification of vitronectin as an extrinsic inducer of cancer stem cell differentiation and tumor formation. Stem Cells (2010) 1.03
A preclinical xenograft model of prostate cancer using human tumors. Nat Protoc (2013) 1.02
New insights into prostate cancer stem cells. Cell Cycle (2013) 1.02
Cytotoxic effects induced by docetaxel, gefitinib, and cyclopamine on side population and nonside population cell fractions from human invasive prostate cancer cells. Mol Cancer Ther (2010) 1.01
Targeting the unique methylation pattern of androgen receptor (AR) promoter in prostate stem/progenitor cells with 5-aza-2'-deoxycytidine (5-AZA) leads to suppressed prostate tumorigenesis. J Biol Chem (2012) 0.98
Activation of c-MET induces a stem-like phenotype in human prostate cancer. PLoS One (2011) 0.98
Epcam, CD44, and CD49f distinguish sphere-forming human prostate basal cells from a subpopulation with predominant tubule initiation capability. PLoS One (2012) 0.97
PC3 prostate tumor-initiating cells with molecular profile FAM65Bhigh/MFI2low/LEF1low increase tumor angiogenesis. Mol Cancer (2010) 0.97
Human prostate side population cells demonstrate stem cell properties in recombination with urogenital sinus mesenchyme. PLoS One (2013) 0.97
The roots of cancer: stem cells and the basis for tumor heterogeneity. Bioessays (2012) 0.96
Prostate cancer stem cells. Clin Genitourin Cancer (2012) 0.96
Identification of a stem cell candidate in the normal human prostate gland. Eur J Cell Biol (2005) 0.95
Overcoming drug resistance and treating advanced prostate cancer. Curr Drug Targets (2012) 0.95
Alpha2beta1 integrin regulates lineage commitment in multipotent human colorectal cancer cells. J Biol Chem (2008) 0.94
Cancer stem cell immunology: key to understanding tumorigenesis and tumor immune escape? Front Immunol (2014) 0.93
Prostate cancer stem cells: deciphering the origins and pathways involved in prostate tumorigenesis and aggression. Oncotarget (2015) 0.93
PINing down the origin of prostate cancer. Sci Transl Med (2010) 0.93
Functions of normal and malignant prostatic stem/progenitor cells in tissue regeneration and cancer progression and novel targeting therapies. Endocr Rev (2008) 0.92
HDAC inhibitor confers radiosensitivity to prostate stem-like cells. Br J Cancer (2013) 0.91
Actions of estrogens and endocrine disrupting chemicals on human prostate stem/progenitor cells and prostate cancer risk. Mol Cell Endocrinol (2011) 0.90
Intestinal epithelial cells in vitro. Stem Cells Dev (2010) 0.89
Growth kinetics of CD133-positive prostate cancer cells. Prostate (2012) 0.89
CD133, Trop-2 and alpha2beta1 integrin surface receptors as markers of putative human prostate cancer stem cells. Am J Transl Res (2010) 0.89
Using induced pluripotent stem cells as a tool for modelling carcinogenesis. World J Stem Cells (2015) 0.88
Modeling the prostate stem cell niche: an evaluation of stem cell survival and expansion in vitro. Stem Cells Dev (2010) 0.88
Dysplasia of human prostate CD133(hi) sub-population in NOD-SCIDS is blocked by c-myc anti-sense. Prostate (2009) 0.88
Prostate stem cells in the development of benign prostate hyperplasia and prostate cancer: emerging role and concepts. Biomed Res Int (2013) 0.87
Two Domains of Vimentin Are Expressed on the Surface of Lymph Node, Bone and Brain Metastatic Prostate Cancer Lines along with the Putative Stem Cell Marker Proteins CD44 and CD133. Cancers (Basel) (2011) 0.87
Lineage relationship of prostate cancer cell types based on gene expression. BMC Med Genomics (2011) 0.87
Prostate progenitor cells proliferate in response to castration. Stem Cell Res (2014) 0.87
CD49f is an efficient marker of monolayer- and spheroid colony-forming cells of the benign and malignant human prostate. PLoS One (2012) 0.87
Combination therapy with epigallocatechin-3-gallate and doxorubicin in human prostate tumor modeling studies: inhibition of metastatic tumor growth in severe combined immunodeficiency mice. Am J Pathol (2010) 0.86
Enrichment of human prostate cancer cells with tumor initiating properties in mouse and zebrafish xenografts by differential adhesion. Prostate (2013) 0.86
Alpha1 and beta1 integrins enhance the homing and differentiation of cultured prostate cancer stem cells. Asian J Androl (2010) 0.86
Regulation of the stem cell marker CD133 is independent of promoter hypermethylation in human epithelial differentiation and cancer. Mol Cancer (2011) 0.85
Human α(2)β(1)(HI) CD133(+VE) epithelial prostate stem cells express low levels of active androgen receptor. PLoS One (2012) 0.85
Role of the microenvironment in ovarian cancer stem cell maintenance. Biomed Res Int (2012) 0.85
Prostate cancer stem cells. Cent European J Urol (2011) 0.84
Retinoic acid represses invasion and stem cell phenotype by induction of the metastasis suppressors RARRES1 and LXN. Oncogenesis (2013) 0.84
Defined conditions for the isolation and expansion of basal prostate progenitor cells of mouse and human origin. Stem Cell Reports (2015) 0.84
MMP-1 is a (pre-)invasive factor in Barrett-associated esophageal adenocarcinomas and is associated with positive lymph node status. J Transl Med (2010) 0.82
Low intensity focused ultrasound (LOFU) modulates unfolded protein response and sensitizes prostate cancer to 17AAG. Oncoscience (2014) 0.81
The androgen receptor and stem cell pathways in prostate and bladder cancers (review). Int J Oncol (2011) 0.81
Targeting prostate cancer stem cells for cancer therapy. Discov Med (2012) 0.80
Evaluating baculovirus as a vector for human prostate cancer gene therapy. PLoS One (2013) 0.80
Epithelial cell-targeted transgene expression enables isolation of cyan fluorescent protein (CFP)-expressing prostate stem/progenitor cells. Transgenic Res (2011) 0.79
Metformin and prostate cancer stem cells: a novel therapeutic target. Prostate Cancer Prostatic Dis (2015) 0.79
Early human prostate adenocarcinomas harbor androgen-independent cancer cells. PLoS One (2013) 0.79
Prostate tumor cells with cancer progenitor properties have high telomerase activity and are rapidly killed by telomerase interference. Prostate (2011) 0.78
Inflammation promotes prostate differentiation. Proc Natl Acad Sci U S A (2014) 0.78
Hunterian Lecture. Characterisation of human prostate epithelial progenitor differentiation in response to androgens. Ann R Coll Surg Engl (2011) 0.78
A Fraction of CD133+ CNE2 Cells Is Made of Giant Cancer Cells with Morphological Evidence of Asymmetric Mitosis. J Cancer (2015) 0.77
Prostate epithelial stem cell culture. Cytotechnology (2003) 0.77
Isolation and analysis of discreet human prostate cellular populations. Differentiation (2015) 0.77
Prostate cancer: regeneration of interest in the prostate. Nat Rev Urol (2009) 0.76
The Androgen Receptor Bridges Stem Cell-Associated Signaling Nodes in Prostate Stem Cells. Stem Cells Int (2016) 0.76
The relationship of cancer stem cells in urological cancers. Cent European J Urol (2013) 0.75
Mouse prostate epithelial luminal cells lineage originate in the basal layer where the primitive stem/early progenitor cells reside: implications for identifying prostate cancer stem cells. Biomed Res Int (2013) 0.75
The many ways to make a luminal cell and a prostate cancer cell. Endocr Relat Cancer (2015) 0.75
Prostate Cancer Stem Cells and Nanotechnology: A Focus on Wnt Signaling. Front Pharmacol (2017) 0.75
s-SHIP expression identifies a subset of murine basal prostate cells as neonatal stem cells. Oncotarget (2016) 0.75
Current Stem Cell Biomarkers and Their Functional Mechanisms in Prostate Cancer. Int J Mol Sci (2016) 0.75
Transcriptome profiling links the intrinsic properties of human prostate basal cells to prostate cancer aggressiveness. Mol Cell Oncol (2016) 0.75
v-Src Oncogene Induces Trop2 Proteolytic Activation via Cyclin D1. Cancer Res (2016) 0.75
Inhibition of the PI3K/AKT/mTOR pathway activates autophagy and compensatory Ras/Raf/MEK/ERK signalling in prostate cancer. Oncotarget (2017) 0.75
The immunosuppressive cytokine interleukin-4 increases the clonogenic potential of prostate stem-like cells by activation of STAT6 signalling. Oncogenesis (2017) 0.75
The polymerase chain reaction: a new epidemiological tool for investigating cervical human papillomavirus infection. BMJ (1989) 3.43
Biochemical transformation of mouse cells by fragments of herpes simplex virus DNA. Cell (1977) 3.38
Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet (1985) 2.76
A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice. J Urol (2000) 2.73
Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43. Am J Hum Genet (1998) 2.59
HPV 16 DNA in normal and malignant cervical epithelium: implications for the aetiology and behaviour of cervical neoplasia. Lancet (1987) 2.38
Polygenic susceptibility to prostate and breast cancer: implications for personalised screening. Br J Cancer (2011) 2.28
Screening for prostate cancer in the UK. Seems to be creeping in by the back door. BMJ (2001) 2.22
Correlation between p53 mutations and antibody staining in breast carcinoma. Br J Surg (1993) 2.09
Ambulatory urodynamics. Br J Urol (1996) 2.06
A case for synchronous reduction of testicular androgen, adrenal androgen and prolactin for the treatment of advanced carcinoma of the prostate. Eur J Cancer (1995) 1.92
MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion. Oncogene (2003) 1.83
Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies. Eur J Cancer (2010) 1.79
The management of men with acute urinary retention. National Prostatectomy Audit Steering Group. Br J Urol (1998) 1.76
Precise microdissection of human prostate cancers reveals genotypic heterogeneity. Cancer Res (1998) 1.74
Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nat Med (1996) 1.68
Tip60 is a nuclear hormone receptor coactivator. J Biol Chem (1999) 1.67
Written consent about sexual function in men undergoing transurethral prostatectomy. Br J Urol (1994) 1.65
Suitability of PSA-detected localised prostate cancers for focal therapy: experience from the ProtecT study. Br J Cancer (2011) 1.62
Basal cells are progenitors of luminal cells in primary cultures of differentiating human prostatic epithelium. Prostate (1998) 1.61
cAMP-responsive element-binding protein regulates vascular endothelial growth factor expression: implication in human prostate cancer bone metastasis. Oncogene (2007) 1.58
Bladder function in healthy volunteers: ambulatory monitoring and conventional urodynamic studies. Br J Urol (1994) 1.51
Clinical outcome and quality of life following enterocystoplasty for idiopathic detrusor instability and neurogenic bladder dysfunction. Br J Urol (1995) 1.50
Long-term outcome related to epidermal growth factor receptor status in bladder cancer. J Urol (1995) 1.49
Screening for bacteriuria in urological patients using reagent strips. Br J Urol (1992) 1.48
p53 and p53-regulated genes in bladder cancer. Br J Urol (1998) 1.46
Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues. Br J Cancer (2005) 1.45
Mucin gene expression in human urothelium and in intestinal segments transposed into the urinary tract. J Urol (2000) 1.45
Human papillomavirus type-16 homologous DNA in normal human ectocervix. Lancet (1986) 1.42
Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med (2016) 1.41
Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder. Br J Cancer (1991) 1.39
The effect of prostatectomy on symptom severity and quality of life. Br J Urol (1996) 1.39
The detection of DNA tumour virus-specific RNA sequences in abnormal human cervical biopsies by in situ hybridization. J Gen Virol (1981) 1.38
Prostate epithelial cell lines form spheroids with evidence of glandular differentiation in three-dimensional Matrigel cultures. Br J Cancer (2001) 1.38
Androgen receptor nuclear translocation is facilitated by the f-actin cross-linking protein filamin. Mol Endocrinol (2000) 1.38
Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer. Br J Cancer (2001) 1.37
Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening. Br J Cancer (2009) 1.36
Nuclear LYRIC/AEG-1 interacts with PLZF and relieves PLZF-mediated repression. Oncogene (2009) 1.33
Detection of latent virus mRNA in tissues using the polymerase chain reaction. J Pathol (1989) 1.33
Rectal, bladder and sexual function after mucosal proctectomy with and without a pelvic reservoir for colitis and polyposis. Br J Surg (1982) 1.33
Structure of the intact transactivation domain of the human papillomavirus E2 protein. Nature (2000) 1.30
C-erbB-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value. J Urol (1996) 1.30
Evaluation of epidermal growth factor receptors in bladder tumours. Br J Cancer (1987) 1.30
Maternal allele loss in Wilms' tumour. Lancet (1989) 1.29
A prospective randomized trial comparing transurethral resection of the prostate and laser therapy in men with chronic urinary retention: The CLasP study. J Urol (2000) 1.27
Cutaneous warts in butchers. Br J Dermatol (1994) 1.24
Co-ordinated changes in expression of cell adhesion molecules in prostate cancer. Eur J Cancer (1997) 1.21
Statistical problems with 'optimal' thresholds in studies of new prognostic factors in urology. BJU Int (2000) 1.21
FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease. Oncogene (1999) 1.21
The behaviour of human oral squamous cell carcinoma in cell culture. J Pathol (1990) 1.19
Comprehensive profiling and localisation of the matrix metalloproteinases in urothelial carcinoma. Br J Cancer (2006) 1.19
Restriction endonuclease analysis of DNA from genital isolates of herpes simplex virus type 2. Infect Immun (1982) 1.19
UHRF1 is a novel molecular marker for diagnosis and the prognosis of bladder cancer. Br J Cancer (2009) 1.18
Transforming growth factor-beta1 up-regulates p15, p21 and p27 and blocks cell cycling in G1 in human prostate epithelium. J Endocrinol (1999) 1.17
Androgen levels in the plasma and prostatic tissues of patients with benign hypertrophy and carcinoma of the prostate. J Endocrinol (1976) 1.16
Cancer of the prostate: early diagnosis by zinc and hormone analysis? Br J Cancer (1979) 1.15
Malignant transformation of human prostatic epithelium is associated with the loss of androgen receptor immunoreactivity in the surrounding stroma. Clin Cancer Res (1999) 1.15
Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer. Br J Cancer (2000) 1.15
Nuclear accumulation of histone deacetylase 4 (HDAC4) coincides with the loss of androgen sensitivity in hormone refractory cancer of the prostate. Eur Urol (2004) 1.14
Latent herpes simplex virus type 1 in normal and Alzheimer's disease brains. J Med Virol (1991) 1.13
Transurethral prostatic resection or laser therapy for men with acute urinary retention: the ClasP randomized trial. J Urol (2001) 1.12
Impact of prostate cancer testing: an evaluation of the emotional consequences of a negative biopsy result. Br J Cancer (2010) 1.12
In vitro modelling of epithelial and stromal interactions in non-malignant and malignant prostates. Br J Cancer (2000) 1.11
Butchers' warts: no evidence for person to person transmission of HPV7. Br J Dermatol (1994) 1.11
Urinary diversion and bladder reconstruction/replacement using intestinal segments for intractable incontinence or following cystectomy. Cochrane Database Syst Rev (2003) 1.08
Transcutaneous electrical nerve stimulation and temporary S3 neuromodulation in idiopathic detrusor instability. J Urol (1996) 1.08
Experimental prostate epithelial morphogenesis in response to stroma and three-dimensional matrigel culture. Cell Growth Differ (2001) 1.08
Detection of herpes simplex virus type 1 gene expression in latently and productively infected mouse ganglia using the polymerase chain reaction. J Gen Virol (1989) 1.07
Tip60 is a co-activator specific for class I nuclear hormone receptors. J Biol Chem (2001) 1.07
A crossover randomized trial of transcutaneous electrical nerve stimulation and oxybutynin in patients with detrusor instability. J Urol (2001) 1.07
The National Prostatectomy Audit: the clinical management of patients during hospital admission. Br J Urol (1995) 1.07
p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate. J Urol (1992) 1.06
The structure of S100A12 in a hexameric form and its proposed role in receptor signalling. Acta Crystallogr D Biol Crystallogr (2002) 1.06
Restriction enzyme analysis of herpesvirus-2 DNA. Lancet (1982) 1.06
Immunohistochemical detection of the epidermal growth factor receptor in paraffin-embedded human tissues. J Pathol (1991) 1.05
P53 and Ki-67 immunoreactivity in human prostate cancer and benign hyperplasia. Br J Urol (1992) 1.05
Long-term follow-up of Anglian Germ Cell Cancer Group surveillance versus patients with Stage 1 nonseminoma treated with adjuvant chemotherapy. Urology (2004) 1.05
Characterization and quantitation of the epidermal growth factor receptor in invasive and superficial bladder tumors. Cancer Res (1989) 1.04
Inverse relationship between the expression of the human papillomavirus type 16 transcription factor E2 and virus DNA copy number during the progression of cervical intraepithelial neoplasia. J Gen Virol (2000) 1.04
bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer. Br J Cancer (1996) 1.03
Systematic review and economic modelling of the relative clinical benefit and cost-effectiveness of laparoscopic surgery and robotic surgery for removal of the prostate in men with localised prostate cancer. Health Technol Assess (2012) 1.03
Cell adhesion molecules in bladder cancer: soluble serum E-cadherin correlates with predictors of recurrence. Br J Cancer (1996) 1.03
Surface localization of sacral foramina for neuromodulation of bladder function. An anatomical study. Eur Urol (1996) 1.02
The three-dimensional structure of human S100A12. Acta Crystallogr D Biol Crystallogr (2001) 1.02
Peroxisome proliferator-activated receptor alpha is an androgen-responsive gene in human prostate and is highly expressed in prostatic adenocarcinoma. Clin Cancer Res (2000) 1.02
The expression of waf-1, p53 and bcl-2 in prostatic adenocarcinoma. Br J Urol (1997) 1.02
Measurement of tissue mechanical characteristics to distinguish between benign and malignant prostatic disease. Urology (2005) 1.02
Long-term monitoring of bladder pressure in chronic retention of urine: the relationship between detrusor activity and upper tract dilatation. J Urol (1988) 1.01
Structure of the human S100A12-copper complex: implications for host-parasite defence. Acta Crystallogr D Biol Crystallogr (2003) 1.01
Immunolocalization and messenger RNA expression of bone morphogenetic protein-6 in human benign and malignant prostatic tissue. Cancer Res (1997) 1.01
Deaths and complications following prostatectomy in 1400 men in the northern region of England. Northern Regional Prostate Audit Group. Br J Urol (1994) 1.01
Serenoa repens (Permixon): a 5alpha-reductase types I and II inhibitor-new evidence in a coculture model of BPH. Prostate (1999) 1.00
Zinc and the steroid endocrinology of the human prostate. J Steroid Biochem (1978) 1.00
Chronic retention of urine. The relationship between upper tract dilatation and bladder pressure. Br J Urol (1986) 1.00
Are diet-prostate cancer associations mediated by the IGF axis? A cross-sectional analysis of diet, IGF-I and IGFBP-3 in healthy middle-aged men. Br J Cancer (2003) 1.00
Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies. Br J Cancer (1998) 0.99
Detection of human papilloma virus type 16 DNA in oral squames from normal young adults. J Oral Pathol Med (1992) 0.99
Correlation of vascular endothelial growth factor expression with fibroblast growth factor-8 expression and clinico-pathologic parameters in human prostate cancer. Br J Cancer (2001) 0.99